SuperworthSutro Biopharma EPS STRO
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- −$17.44
- Latest quarter, Q2 FY26
- −$2.33
- Fiscal year 2025
- −$22.60
Sutro Biopharma's earnings per share was −$17.44 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$2.33.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$22.60 | n/a |
| FY2024 | −$30.10 | n/a |
| FY2023 | −$17.90 | n/a |
| FY2022 | −$23.70 | n/a |
| FY2021 | −$22.80 | n/a |
| FY2020 | −$9.30 | n/a |
| FY2019 | −$24.30 | n/a |
| FY2018 | −$712.50 | n/a |
| FY2017 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$2.33 | n/a | −$17.44 | |
| Q1 FY26 | −$2.94 | n/a | −$16.46 | |
| Q4 FY25 | −$5.47 | n/a | −$22.60 | |
| Q3 FY25 | −$6.70 | n/a | −$25.93 | |
| Q2 FY25 | −$1.35 | n/a | −$25.13 | |
| Q1 FY25 | −$9.08 | n/a | −$29.68 | |
| Q4 FY24 | −$8.80 | −273% | −$30.10 | |
| Q3 FY24 | −$5.90 | n/a | −$16.20 | |
| Q2 FY24 | −$5.90 | n/a | −$18.40 | |
| Q1 FY24 | −$9.50 | n/a | −$18.90 | |
| Q4 FY23 | $5.10 | n/a | −$17.90 | |
| Q3 FY23 | −$8.10 | n/a | −$29.10 |
Against its peers
Companies in Healthcare nearest Sutro Biopharma's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| STROSutro Biopharma | −$17.44 | |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ELMDElectromed | $1.31 | +56% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| ICCCImmucell | $0.08 | −58% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| Peer median | $0.71 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Sutro Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.